about
Obtaining reliable information from minute amounts of RNA using cDNA microarraysParaneoplastic chorea: case study with autopsy confirmation.Pathologically proven cavernous angiomas of the brain following radiation therapy for pediatric brain tumors.Pineal cyst apoplexy: case report and review of the literature.Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors.Whole-transcriptome analysis of chordoma of the skull base.Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients.Surgical management of lateral-ventricle metastases: report of 29 cases in a single-institution experience.Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation.Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.Hypoxia potentiates glioma-mediated immunosuppressionLow rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas.The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities.Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas.Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.Overexpression and constitutive nuclear localization of cohesin protease Separase protein correlates with high incidence of relapse and reduced overall survival in glioblastoma multiformeIntratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.Myoblast-derived neuronal cells form glutamatergic neurons in the mouse cerebellum.Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastomaThe characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats.Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.F11R is a novel monocyte prognostic biomarker for malignant gliomaSustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growthPDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivoSignal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis.Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma.Neutrophils promote the malignant glioma phenotype through S100A4.Primitive neuroectodermal tumors, embryonal tumors, and other small cell and poorly differentiated malignant neoplasms of the central and peripheral nervous systems.Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB networkThe tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.Limitations of stereotactic biopsy in the initial management of gliomas.Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.IGFBP2 potentiates nuclear EGFR-STAT3 signaling.Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.PD-L1 expression and prognostic impact in glioblastoma.The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
P50
Q24796766-A8479F9C-61BD-467C-9FFC-B6D061C41F68Q30700145-8CCB6BBF-F22D-4456-84DF-DD0549179BD6Q30821359-066B83C1-B751-4916-873F-D7A2F2D3111DQ31018170-8977F7B9-E3BF-4187-B95E-903F2062F3F4Q33270666-31E86F4A-3989-4536-822F-E6A2DCD90BC3Q33276132-23AEDA1C-A4BD-4FEB-8012-D91300584A2EQ33385439-9B797143-C136-486A-A41B-85B2A43997EBQ33491732-7323CF18-AB7E-4469-A5A3-9DCF9057D73AQ33752387-05D08D8A-41B1-4209-8D60-CD4DF506C7D5Q33779928-78788179-0480-40F2-B376-6BAB18085124Q33809268-7EF8BF65-F16F-4902-8491-EC96AD71BF4CQ33859265-58F643B9-7C16-43CA-99A8-739A2FDCD2C3Q34004853-1C6751A4-DEA3-42DC-BDF5-546C16DDD781Q34062021-1D03B5F7-05C2-45E3-B712-57DAFC10728CQ34117204-F5C3163D-62DD-470C-BCF6-F9ACDA2ED53AQ34159936-1924EB3D-2A83-459D-9431-6A0E7ACF05C9Q34393758-BEA53415-C114-4194-BBBC-EA04E13A7935Q34713799-57A84E59-9F16-4BEA-BB0E-C48EE85BAA02Q34714132-95E8E866-3493-45A7-B551-A74DEB59F1E5Q34736639-93257696-18F6-4930-8C9E-7521F5ADFCE8Q34768422-0FC97885-190B-4BB3-BBDD-DF61933F6709Q34980413-188F7D59-1D11-4BAE-A278-6224A8F035F5Q35023227-6D6EDE6E-C65E-4473-92DB-DF1B490546CDQ35070046-DAB31BAE-226A-4C11-AA5E-C48E1BA44CF6Q35080265-6E70C8E1-B8C6-4D76-92AB-BB8A5737AE8DQ35091330-2867CC7C-5D86-4767-A97D-60F0B36D6D26Q35212521-95A4512F-01A0-4B4F-863F-3C5B88A145F1Q35388292-1D73D428-7AFB-4B9B-ABAB-3721E4ABFAF3Q35577475-D50A3FE9-7DDE-43BB-869A-38E0753BE117Q35689773-99E05206-4A90-4CF8-BC05-0D829B62B0F5Q35807732-8E0DF1D0-B1F9-4F14-B250-8B2A19291EF2Q35871559-1844D07F-7AAF-480A-B193-E3F0B54F51A4Q35894795-DAAC7706-6BBF-453A-A9AE-D78665DAFE36Q35894905-056C015C-4F8D-4AB3-9DED-6C6F7414B3B2Q36189855-E0A7E7F3-CE22-4A90-8C05-29D92935D1F9Q36272539-3607EDE4-A51A-4C8F-9776-29E87803F812Q36493843-AA63ACB6-7114-4E7C-849D-C0ED6BFA48ACQ36580474-BD7959E3-966A-4773-A60F-6CDF395EEFB2Q36645979-75618C58-36B8-42E0-B2B8-A393781893A4Q36785139-987730F0-E591-4CAA-85CC-F7DABEF46E9F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Greg N Fuller
@nl
Greg N Fuller
@sl
Greg N. Fuller
@en
Greg N. Fuller
@es
type
label
Greg N Fuller
@nl
Greg N Fuller
@sl
Greg N. Fuller
@en
Greg N. Fuller
@es
altLabel
G Fuller
@en
GN Fuller
@en
Greg N. Fuller
@en
Gregory N. Fuller
@en
prefLabel
Greg N Fuller
@nl
Greg N Fuller
@sl
Greg N. Fuller
@en
Greg N. Fuller
@es
P106
P1153
7202991518
P21
P31
P496
0000-0001-9447-2647